89bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update | BioSpace
   - Reported positive topline results from ENTRIGUE Phase 2
89bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
   - Reported positive topline results from ENTRIGUE Phase 2
Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress
Revolution Medicines, Inc.First two RAS(ON) Inhibitor drug candidates advance into
HeartSciences Provides Corporate Update and Reports Fiscal 2022 Financial Results
MyoVista FDA De Novo dovrebbe essere reintrodotto nell'anno fiscale in
HeartSciences Provides Corporate Update and Reports Fiscal 2022 Financial Results
MyoVista FDA De Novo dovrebbe essere reintrodotto nell'anno fiscale in
HeartSciences Provides Corporate Update and Reports Fiscal 2022 Financial Results
Heart Test Labs, Inc.MyoVista FDA De Novo dovrebbe essere reintrodotto